The trading price of Merck & Co. Inc. (NYSE:MRK) closed lower on Tuesday, July 20, closing at $76.17, -1.14% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $75.9532 and $78.13. The company’s P/E ratio in the trailing 12-month period was 27.54, while its 5Y monthly beta was 0.42. In examining the 52-week price action we see that the stock hit a 52-week high of $83.72 and a 52-week low of $68.38. Over the past month, the stock has lost -0.57% in value.
Merck & Co. Inc., whose market valuation is $192.57 billion at the time of this writing, is expected to release its quarterly earnings report Jul 29, 2021. The dividend yield on the company stock is 3.41%, while its Forward Dividend ratio is 2.60. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $1.46 per share this quarter, however they have predicted annual earnings per share of $6.21 for 2021 and $6.65 for 2022. It means analysts are expecting annual earnings per share growth of 4.50% this year and 7.10% next year.
Analysts have forecast the company to bring in revenue of $11.58 billion for the current quarter, with the likely lows of $10.81 billion and highs of $13.33 billion. The average estimate suggests sales will likely up by 6.50% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $48.59 billion. The company’s revenue is forecast to grow by 1.20% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Merck & Co. Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest MRK has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned MRK a recommendation rating is 21. Out of them, 6 rate it a Hold, while 11 recommend Buy, whereas 4 assign an Overweight rating. 0 analyst(s) have tagged Merck & Co. Inc. (MRK) as Underweight, while 0 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 2.54, which symbolizes a positive outlook. A quick review shows that MRK’s price is currently -1.66% off the SMA20 and 0.54% off the SMA50. The RSI metric on the 14-day chart is currently showing 44.41, and weekly volatility stands at 1.77%. When measured over the past 30 days, the indicator reaches 1.26%. Merck & Co. Inc. (NYSE:MRK)’s beta value is currently sitting at 0.42, while the Average True Range indicator is currently displaying 1.14. With analysts defining $78.00-$107.00 as the low and high price targets, we arrive at a consensus price target of $93.52 for the trailing 12-month period. The current price is about -2.4% off the estimated low and -40.48% off the forecast high, based on this estimate. Investors will be thrilled if MRK’s share price rises to $94.70, which is the median consensus price. At that level, MRK’s share price would be -24.33% below current price.
To see how Merck & Co. Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: MRK stock’s performance was -1.14% in the latest trading, and 0.59% in the past year, while Eli Lilly and Company (LLY) has traded 0.38% on the day and positioned 40.70% higher than it was a year ago. Another comparable company Johnson & Johnson (JNJ) saw its stock close 0.94% higher in the most recent trading session but was up 12.60% in a year. Furthermore, Sanofi (SNY) showed an increase of 0.49% on the day while its price kept declining at -4.41% over the past year. Merck & Co. Inc. has a P/E ratio of 27.54, compared to Eli Lilly and Company’s 35.20 and Johnson & Johnson’s 29.76. Also in last trading session, the S&P 500 Index has surged 1.52%, while the Dow Jones Industrial also saw a positive session, up 1.62% on the day.
An evaluation of the daily trading volume of Merck & Co. Inc. (NYSE:MRK) indicates that the 3-month average is 12.29 million. However, this figure has increased over the past 10 days to an average of 7.88 million.
Currently, records show that 2.53 billion of the company’s shares remain outstanding. The insiders hold 0.10% of outstanding shares, whereas institutions hold 75.10%. The stats also highlight that short interest as of Jun 14, 2021, stood at 22.07 million shares, resulting in a short ratio of 1.8 at that time. From this, we can conclude that short interest is 0.87% of the company’s total outstanding shares. It is noteworthy that short shares in June were up slightly from the previous month’s figure, which was 20.79 million. However, since the stock’s price has seen -2.34% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.